{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:54:46Z","timestamp":1785261286628,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009250","name":"National Institute for Social Care and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Modelling suggests hepatitis C virus (HCV) elimination is possible among men who have sex with men (MSM), with key screening groups including HIV\u2010diagnosed MSM and MSM using pre\u2010exposure prophylaxis (PrEP). Mathematical modelling was used to determine the cost\u2010effectiveness of HCV case\u2010finding strategies among MSM from the provider perspective, and to determine which interventions could achieve a 90% reduction in HCV incidence over 2015\u20132030. At baseline, we assumed symptomatic screening in HIV\u2010negative MSM (including PrEP users) and 12\u2010monthly screening among HIV\u2010diagnosed MSM. Improved case\u2010finding strategies included screening alongside HIV testing in HIV\u2010negative MSM not using PrEP (PrEP non\u2010users); 12\/6\/3\u2010monthly screening in PrEP users; and 6\u2010monthly screening in HIV\u2010diagnosed MSM, with the cost\u2010effectiveness being compared incrementally. Costs (GBP) and quality\u2010adjusted life years (QALYs) were assessed to estimate the mean incremental cost\u2010effectiveness ratio (ICER) with a time horizon to 2050, compared to a willingness\u2010to\u2010pay threshold of \u00a320,000\/QALY. From the baseline, the most incrementally cost\u2010effective strategy is to firstly undertake: (1) 12\u2010monthly HCV screening of PrEP users (gaining 6715 QALYs with ICER \u00a31760\/QALY), followed by (2) HCV screening among PrEP non\u2010users alongside HIV testing (gaining 7048 QALYs with ICER \u00a34972\/QALY). Compared to the baseline, this combined strategy would cost \u00a346.9 (95%CrI \u00a325.3\u2013\u00a366.9) million and achieve the HCV elimination target in 100% of model runs. Additional screening incurs ICERs &gt;\u00a320,000\/QALY compared to this combined strategy. In conclusion, HCV elimination can be achieved cost\u2010effectively among UK MSM. Policymakers should consider scaling\u2010up HCV screening in HIV\u2010negative MSM, especially PrEP users, for achieving this target.<\/jats:p>","DOI":"10.1111\/jvh.13503","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T07:39:51Z","timestamp":1616571591000},"page":"897-908","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The cost\u2010effectiveness of case\u2010finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK"],"prefix":"10.1111","volume":"28","author":[{"given":"Louis","family":"Macgregor","sequence":"first","affiliation":[{"name":"Population Health Sciences University of Bristol Bristol UK"},{"name":"National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Ward","sequence":"additional","affiliation":[{"name":"Population Health Sciences University of Bristol Bristol UK"},{"name":"National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha K","family":"Martin","sequence":"additional","affiliation":[{"name":"Population Health Sciences University of Bristol Bristol UK"},{"name":"Division of Infectious Diseases and Global Public Health University of California San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Population Health Sciences University of Bristol Bristol UK"},{"name":"National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation Bristol UK"},{"name":"Department of Sexual Health, Cardiff Vale University Health Board Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-9808","authenticated-orcid":false,"given":"Monica","family":"Desai","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Excellence London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ford","family":"Hickson","sequence":"additional","affiliation":[{"name":"Sigma Research, Faculty of Public Health &amp; Policy London School of Hygiene and Tropical Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Weatherburn","sequence":"additional","affiliation":[{"name":"Sigma Research, Faculty of Public Health &amp; Policy London School of Hygiene and Tropical Medicine London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences University of Bristol Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8291-5890","authenticated-orcid":false,"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"Population Health Sciences University of Bristol Bristol UK"},{"name":"National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30303-4"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574887114666190306154650"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13638"},{"key":"e_1_2_11_6_1","unstructured":"World Health Organization (WHO).Combating hepatitis B and C to reach elimination by 2030 2016."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa021"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12050"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13297"},{"key":"e_1_2_11_10_1","unstructured":"BoerekampsA van denBerkG LauwF et al.Substantial decline in acute HCV infections among Dutch HIV+MSM after DAA roll out. Conference on Retroviruses and Opportunistic Infections (CROI) 2015 Seattle Washington Abstract 137LB 2017."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1124"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.010"},{"key":"e_1_2_11_13_1","unstructured":"Public Health England (PHE).Progress towards ending the HIV epidemic in the United Kingdom 2018."},{"key":"e_1_2_11_14_1","unstructured":"Terrence Higgens Trust 2019.https:\/\/www.iwantprepnow.co.uk\/. Accessed March 30 2021."},{"key":"e_1_2_11_15_1","unstructured":"Department of Health and Social Care UK 2020.https:\/\/www.gov.uk\/government\/news\/hiv\u2010drug\u2010prep\u2010to\u2010be\u2010available\u2010across\u2010england. Accessed March 30 2021."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462313000160"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx075"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu447"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0169-5"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e6d51"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.31"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30089-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.41.1900598"},{"issue":"2","key":"e_1_2_11_27_1","first-page":"e25252","article-title":"Persistence with HIV Preexposure Prophylaxis in the United States, 2012\u20132017","volume":"22","author":"Huang YA","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_11_28_1","unstructured":"NHS England.Clinical Commissioning Policy Proposition: Pre\u2010exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults 2016."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.42.17-00192"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw075"},{"key":"e_1_2_11_31_1","unstructured":"British Association for Sexual Health and HIV.2017 interim update of the 2015 BASHH National Guidelines for the Management of Viral Hepatitides;2017."},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055373"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03657.x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62035-8"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-919"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10210"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.007"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14519"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta11110"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12338"},{"key":"e_1_2_11_41_1","unstructured":"The National Institute for Health and Care Excellence (NICE).Guide to the methods of technology appraisal 2013 2013."},{"issue":"11","key":"e_1_2_11_42_1","first-page":"1351","article-title":"Hepatitis C: diagnosis and treatment","volume":"81","author":"Wilkins T","year":"2010","journal-title":"Am Fam Physician"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13178-013-0119-4"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12629"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3945-z"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70341-9"},{"key":"e_1_2_11_47_1","unstructured":"Public Health England (PHE).HIV in the United Kingdom: 2013 Report 2013."},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4524-z"},{"issue":"3","key":"e_1_2_11_49_1","first-page":"379","article-title":"Who to screen for hepatitis C? A cost\u2010effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups","volume":"82","author":"Opstaele L","year":"2019","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210179"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis382"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.19.1690"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12106"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13503","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:07:22Z","timestamp":1693562842000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/jvh.13503"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13503","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2021-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}